Table 1 Baseline demographics and characteristicsa
From: Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
All patients (N = 532) | Malignancy patients (n = 20) | |
|---|---|---|
Women | 301 (57) | 12 (60) |
Adolescents | 28 (5) | 0 |
Age, median (Q1, Q3), y | 33 (25, 45) | 52 (32, 65) |
Follow-up, median (Q1, Q3), mo | 58 (34, 74) | 48 (17, 81) |
No. of denosumab doses received, median (Q1, Q3) | 34 (18, 61) | 22 (11, 40) |
GCTB disease type | ||
Primary resectable | 168 (32) | 6 (30) |
Primary unresectable | 94 (18) | 2 (10) |
Recurrent resectable | 85 (16) | 2 (10) |
Recurrent unresectable | 185 (35) | 10 (50) |
Prior GCTB surgery | ||
Yes | 276 (52) | 12 (60) |
No | 256 (48) | 8 (40) |
Prior GCTB radiotherapy | ||
Yes | 52 (10) | 4 (20) |
No | 480 (90) | 16 (80) |